SkinBioTherapeutics Statistics
Total Valuation
SkinBioTherapeutics has a market cap or net worth of GBP 26.85 million. The enterprise value is 24.10 million.
Market Cap | 26.85M |
Enterprise Value | 24.10M |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
Earnings Date | Nov 29, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
SkinBioTherapeutics has 226.09 million shares outstanding. The number of shares has increased by 11.47% in one year.
Shares Outstanding | 226.09M |
Shares Change (YoY) | +11.47% |
Shares Change (QoQ) | +2.45% |
Owned by Insiders (%) | 3.63% |
Owned by Institutions (%) | 39.12% |
Float | 175.40M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 128.52 |
PB Ratio | 6.19 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -8.36 |
EV / Sales | 149.12 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -7.72 |
Financial Position
The company has a current ratio of 6.57, with a Debt / Equity ratio of 2.66.
Current Ratio | 6.57 |
Quick Ratio | 6.48 |
Debt / Equity | 2.66 |
Debt / EBITDA | n/a |
Debt / FCF | -0.03 |
Interest Coverage | -380.12 |
Financial Efficiency
Return on equity (ROE) is -118.64% and return on invested capital (ROIC) is -74.81%.
Return on Equity (ROE) | -118.64% |
Return on Assets (ROA) | -61.18% |
Return on Capital (ROIC) | -74.81% |
Revenue Per Employee | 14,695 |
Profits Per Employee | -262,269 |
Employee Count | 11 |
Asset Turnover | 0.05 |
Inventory Turnover | 0.89 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.80% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -47.80% |
50-Day Moving Average | 11.62 |
200-Day Moving Average | 11.55 |
Relative Strength Index (RSI) | 45.61 |
Average Volume (20 Days) | 478,913 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SkinBioTherapeutics had revenue of GBP 161,648 and -2.88 million in losses. Loss per share was -0.02.
Revenue | 161,648 |
Gross Profit | 101,676 |
Operating Income | -3.03M |
Pretax Income | -3.04M |
Net Income | -2.88M |
EBITDA | -3.00M |
EBIT | -3.03M |
Loss Per Share | -0.02 |
Balance Sheet
The company has 2.84 million in cash and 97,050 in debt, giving a net cash position of 2.74 million or 0.01 per share.
Cash & Cash Equivalents | 2.84M |
Total Debt | 97,050 |
Net Cash | 2.74M |
Net Cash Per Share | 0.01 |
Equity (Book Value) | 3.65M |
Book Value Per Share | 0.02 |
Working Capital | 2.79M |
Cash Flow
In the last 12 months, operating cash flow was -3.02 million and capital expenditures -104,753, giving a free cash flow of -3.12 million.
Operating Cash Flow | -3.02M |
Capital Expenditures | -104,753 |
Free Cash Flow | -3.12M |
FCF Per Share | -0.01 |
Margins
Gross Margin | 62.90% |
Operating Margin | -1,877.21% |
Pretax Margin | -1,882.15% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -1,931.00% |
Dividends & Yields
SkinBioTherapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -11.47% |
Shareholder Yield | -11.47% |
Earnings Yield | -13.90% |
FCF Yield | -11.63% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |